LNGR


Longevity Thematic ETF

Fund Summary

The Global X Longevity Thematic ETF (LNGR) seeks to invest in companies positioned to serve the world’s growing senior population through exposure to health care, pharmaceuticals, senior living facilities and other sectors that contribute to increasing lifespans and extending quality of life in advanced age.

Fund Objective

The Global X Longevity Thematic ETF seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Indxx Global Longevity Thematic Index.

Why LNGR?

High Growth Potential

LNGR enables investors to access high growth potential through companies at the leading edge of a long-term, structural demographic trend affecting multiple sectors of the global economy.

Unconstrained Approach

LNGR's composition transcends classic sector, industry, and geographic classifications by tracking an emerging theme.

ETF Efficiency

In a single trade, LNGR delivers access to dozens of companies with high exposure to the Longevity theme.

Fund Details As of 3/29/17

Ticker LNGR
Primary Exchange NASDAQ
CUSIP 37954Y772
ISIN US37954Y7720
Net Assets $1,689,053.52
Management Fee 0.68%
Fee Waiver* -0.18%
Annual Fund Operating Expense 0.50%
Inception Date 5/9/16
Shares Outstanding 100,000
30-Day SEC Yield 0.73%
Distribution Frequency Annually
Distribution Calendar

*Pursuant to an Expense Limitation Agreement, the Adviser has contractually agreed to reimburse or waive fees and/or limit Fund expenses to the extent necessary to assure that the operating expenses of the Fund [exclusive of taxes, brokerage fees, commissions, and other transaction expenses, interest, and extraordinary expenses (such as litigation and indemnification expenses)] will not exceed 0.50% of the Fund’s average daily net assets per year until at least April 1, 2018. Total Annual Fund Operating Expenses apply after Fee Waiver and/or Expense Reimbursement.

Fund Prices

As of 3/29/17
NAV Price
Net Asset Value $16.89 Closing Price $17.00
Daily Change $0.09 0.56% Daily Change $0.12 0.68%

Performance History

Cumulative %

Data as of month end (2/28/17)

Fund NAV Closing Price Index
1 Month 5.31% 5.62% 5.37%
3 Months 10.93% 11.23% 11.11%
6 Months 2.55% 2.84% 2.80%
Since Inception 9.84% 12.64% 10.28%

Cumulative %

Data as of quarter end (12/31/16)

Fund NAV Closing Price Index
Since Inception -0.12% 3.01% 0.20%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized Return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Fund Characteristics As of 3/29/17

Return on Equity 13.80%
Average Market Cap $13,233.00 M
2016 2017
Price-to-earnings 28.83 26.32
Price-to-book value 3.79 3.47

Source: AltaVista Research, LLC

Top 10 Holdings

As of 3/29/17
Net Assets % Name Market Price ($) Shares Held Market Value ($)
3.66 VERTEX PHARMACEUTICALS IN 108.01 572 61,781.72
3.65 BOSTON SCIENTIFIC CORP 24.71 2,497 61,700.87
3.58 INCYTE CORP 139.28 434 60,447.52
3.46 STRYKER CORP 131.90 443 58,431.70
3.33 CELGENE CORP 124.09 453 56,212.77
3.32 BECTON DICKINSON AND CO 183.87 305 56,080.35
3.18 ABBVIE INC 65.77 817 53,734.09
3.06 ZIMMER BIOMET HOLDINGS IN 121.37 426 51,703.62
3.03 MEDTRONIC PLC 81.14 630 51,118.20
2.94 VENTAS INC 64.66 769 49,723.54
Holdings are subject to change.

Investing involves risk, including the possible loss of principal. The investable universe of companies in which the Fund may invest may be limited. The Fund invests in securities of companies engaged in Healthcare, Pharmaceutical, Biotechnology and Medical Device sectors. These sectors can be affected by government regulations, expiring patents, rapid product obsolescence, and intense industry competition. In addition to normal risks associated with investing, international investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. The fund is non-diversified which represents a heightened risk to investors.

Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Global X NAVs are calculated using prices as of 4:00 PM Eastern Time. The closing price is the Mid-Point between the Bid and Ask price as of the close of exchange. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s Shares typically do not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s full or summary prospectus, which may be obtained by calling 1-888-GX-FUND-1 (1.888.493.8631), or by visiting globalxfunds.com. Read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, FTSE, Standard & Poors, NASDAQ, S-Network, Indxx, or MSCI nor do these companies make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO nor Global X is affiliated with Solactive AG, FTSE, Standard & Poors, NASDAQ, S-Network, Indxx, or MSCI.